A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency

Start Date18 Sep 2014

Sponsor / Collaborator

Synageva BioPharma Corp.

NCT02112994 / CompletedPhase 2

A Multi-Center, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency

This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).

Start Date24 Jun 2014

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

NCT02193867 / TerminatedPhase 2

A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.

Start Date06 Jun 2014

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

100 Clinical Results associated with Sebelipase Alfa

100 Translational Medicine associated with Sebelipase Alfa

100 Patents (Medical) associated with Sebelipase Alfa

Literatures (Medical) associated with Sebelipase Alfa

01 Dec 2022·Genome medicine

Rapid whole genome sequencing of critically ill pediatric patients from genetically underrepresented populations

Letter

Author: Alsheikh-Ali, Alawi ; Al Awadhi, Mohamed ; Bitzan, Martin ; Taylor, Alan ; Yavuz, Lemis ; Abuhammour, Walid ; Al Khayat, Abdulla ; Alfalasi, Roudha ; El Naofal, Maha ; Al Maazmi, Munira Mahmoud ; Ramaswamy, Sathishkumar ; Jadhav, Devendrasing ; Janjua, Dalwinder ; Jain, Ruchi ; Abulhoul, Hamda ; Shankar, Shiva ; Shenbagam, Shruti ; Halabi, Nour ; Abou Tayoun, Ahmad N ; Yaslam, Sawsan

Abstract:

We describe a case series of five infants (age range: 1–90 days; 4 females and 1 male) who presented to Al Jalila Children’s intensive care units (ICU) with complex multisystem disorders. Patients were Emirati, Kenyan, Jordanian, Filipino, or Pakistani. Trio rapid whole genome sequencing (rWGS) was performed on all five patients and their parents within the hospital’s genomics facility. Results were returned within ~37 h from blood sample draws and were diagnostic in 3 out of 5 patients. Positive findings were a homozygous pathogenic variant in POMT1 gene causing muscular dystrophydystroglycanopathy, a mosaic tetrasomy of the short arm of chromosome 12 (12p13.33p11.1) causing Pallister-Killian syndrome, and compound heterozygous pathogenic variants in the LIPA gene causing lysosomal acid lipase deficiency and Wolman disease. The rWGS analysis provided fast and precise diagnostic findings in those 3 patients and also aided in devising better management plans for them in the intensive care setting. For example, the 3-month-old infant with pathogenic variants in the LIPA gene is now a candidate for an FDA-approved, potentially lifesaving enzyme replacement therapy (sebelipase alfa). Our case series emphasize the feasibility and utility of rWGS in pediatric intensive care setting, in a diverse population that has long been underserved in genomic services. Significant investments in local healthcare infrastructure are needed, globally, for more equitable access of genomic medicine among vulnerable patients.

02 Sep 2022·Medicine

15-Year progression to liver cancer in the lack of treatment for lysosomal acid lipase deficiency: A case report

Article

Author: Perales, Simone Reges ; de Ataíde, Elaine Cristina ; Sevá-Pereira, Tiago ; Veiga, Clauber Teles ; Greca, Raquel Dias ; de França, Eloy Vianey Carvalho ; de Campos Mazo, Daniel Ferraz ; Cunha-Silva, Marlone ; de Moraes, Priscilla Brito Sena ; Monici, Leonardo Trevizan

Rationale::

Lysosomal acid lipase deficiency (LAL-D) is a poorly diagnosed genetic disorder characterized by the accumulation of cholesteryl esters and triglycerides in many tissues, leading to dyslipidemia and cardiovascular complications. In the liver, deposits are found within hepatocytes and Kupffer cells, generating microvesicular steatosis, progressive fibrosis, and cirrhosis. Sebelipase alfa is the target therapy which can improve laboratory changes and reduce the progression of liver damage, but this is not yet widely available.

Patient Concerns::

We are reporting a 15-year follow-up of a Brazilian man who was diagnosed with cirrhosis at age 43 and with LAL-D at age 53, but he has never been treated with sebelipase alfa for economic reasons. During the coronavirus disease 2019 (COVID-19) pandemic, he lost follow-up and missed three 6-month ultrasound exams for liver cancer screening.

Diagnosis::

At age 58, a remarkable deterioration in liver function was observed and he was diagnosed with hepatocellular carcinoma (HCC) outside the Milan Criteria (two nodules measuring 48mm and 25mm). Three other individuals with LAL-D and progression to liver cancer have been reported so far and none of them underwent enzyme replacement therapy: an 11-year-old girl with HCC, a 51-year-old male with cholangiocarcinoma, and a 21-year-old male with hepatocellular-cholangiocarcinoma. The latter had the same mutation in the gene LIPA as our patient, but a relationship between this variant and malignancies has not yet been established.

Lessons::

We emphasize how important is to treat LAL-D patients after diagnosis in order to avoid worsening liver function and progression to neoplasms. Untreated individuals should be considered at a higher risk but the most appropriate liver cancer screening program for this subgroup is still unknown.

01 Aug 2022·Canadian liver journal

Early diagnosis and successful long-term management of a rare, severe lysosomal acid lipase deficiency/Wolman disease patient: Infancy to age five

Author: Beecroft, Michael ; Castilloux, Julie ; Cossette, Antoine ; Faure, Christophe ; Benlamlih, Sami ; Abel, Florian ; Laflamme, Julie ; Bouffard, Chantal ; Francis, Mira ; Drouin, Régen

BACKGROUND: This report describes a unique case of long-term survival of a young girl who was diagnosed with severe, rapidly progressive lysosomal acid lipase deficiency (LAL-D; historically “Wolman disease”) at three months of age and began receiving therapeutic interventions at four months of age. This disease involves rapidly progressive multisystemic impairments and limited survival (6–12 months) without treatment. METHODS: Case report taking into account clinical aspects and patient management including a semi-structured interview with the main family caregiver. RESULTS: Presentation at two months of age: severe malnutrition and chronic diarrhea; hypoalbuminemia; low iron, vitamin A, and vitamin D levels; high triglyceride levels; profound anemia; thrombocytopenia; adrenal calcifications; and mild hepatosplenomegaly. Enzyme replacement therapy (ERT) with sebelipase alfa, parenteral nutrition, and a low-fat diet began at age four months. The patient has received sebelipase alfa for >5 years with good tolerability and is thriving, with a body mass index of 16.35 kg/m2 (80th percentile) despite a stature delay (height <3rd percentile), and mild developmental delay. Optimal medical management requires that family caregivers and health professionals have the knowledge and skills to provide appropriate care and supports multidisciplinary teams through transfer of knowledge to all stakeholders. Effective coordination of services and activities related to child health and development, including navigation of administrative and financial barriers, is also imperative. CONCLUSIONS: Formerly fatal in untreated infants, severe LAL-D, when diagnosed early, can be promptly and effectively treated by combining sebelipase alfa ERT, modified diet, involvement of family caregivers, and multidisciplinary team collaboration.

News (Medical) associated with Sebelipase Alfa

29 Feb 2024

·www.pharmaceutical-technology.com

NHS expedites availability of Belumosudil for chronic GVHD

The once-daily tablet hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Credit: fizkes / Shutterstock.com. The National Health Service (NHS) in the UK has expedited the availability of the new drug, Belumosudil (Rezurock), for cancer patients with chronic graft versus host disease (GVHD). The decision provides a treatment that can be administered in the at-home setting, reducing hospital visits. Administered as a once-daily tablet, Belumosudil hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Clinical trials have demonstrated that up to three-quarters of the subjects responded to the therapy, with significant effectiveness in treating symptoms affecting the mouth, intestine or joints. The treatment is accessible through the NHS England’s Innovative Medicines Fund, which fast-tracks the delivery of the most promising non-cancer drugs to patients. See Also: AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval Chronic GVHD is a rare but serious condition that can occur after a life-saving stem cell transplant. White blood cells in the donated tissue attack the patient’s organs and weaken their immune system. Approximately one-third of patients who receive stem cell or bone marrow transplants for blood cancers such as leukaemia and lymphoma can develop chronic GVHD. Around 1,200 patients in England undergo such transplants each year. Around 400 go on to develop the condition, which is sometimes mild but for one in ten cases is fatal. For half of patients with chronic GVHD, existing therapies such as pentostatin, rituximab and imatinib are ineffective. Belumosudil will now be made available for 200 severely affected patients who have not responded to two previous therapies. This development comes after the NHS decided to fast-track the funding for the drug based on clinical guidance from the UK National Institute of Health and Care Excellence ( Nice ). Belumosudil is the fourth therapy offered to patients through the Innovative Medicines Fund. In September 2023, the NHS used the fund to roll out Sebelipase alfa, a therapy for treating Wolman’s disease, a rare genetic ailment. NHS England specialised services medical director James Palmer stated: “This rollout is a real breakthrough for patients with graft versus host disease and it will help people living with this debilitating condition effectively manage their symptoms and enhance their quality of life and daily functioning. “It’s great news that the NHS has been able to fast-track funding for a treatment which will have a significant impact for hundreds of patients over the coming years.”

Clinical Result

27 Nov 2023

·www.pmlive.com

AstraZeneca's rare disease unit receives NICE recommendation for Wolman disease therapy in infants

AstraZeneca's rare disease unit has received a recommendation from the National Institute for Health and Care Excellence (NICE) for the use of its enzyme replacement therapy in infants with Wolman disease. Alexion’s Kanuma (sebelipase alfa), which has been specifically recommended for use in patients who are aged two years or younger when administration begins, will now become the first treatment available on the NHS for the rapidly-progressive rare genetic disease. Occurring in around one in 350,000 births, Wolman disease causes a build-up of fat in cells in the liver, heart, blood vessels and digestive system. Symptoms in infants include enlarged liver and spleen, poor weight gain, low muscle tone, jaundice, vomiting, diarrhoea, developmental delay and anaemia. Until now, standard care for the disease has been palliative and limited to managing symptoms, with patients normally not surviving past the age of one without treatment. Administered as weekly intravenous infusions which can be given at home alongside a restricted low-fat diet, Kanuma works by replacing an enzyme missing in the body. Some patients may also have a blood and marrow/stem cell transplant. NHS chief executive, Amanda Pritchard, said: “I am delighted the NHS can now, for the first time, offer a life-changing treatment to families facing this enormously difficult condition. “Where previously there were no treatments available for infants facing this debilitating disease, this new therapy could save families from facing indescribable grief and allow more children… to grow up, go to school and live normal lives.” The therapy will now be fast-tracked via NHS England’s Innovative Medicines Fund to enable routine patient access up to five months earlier than would otherwise be the case. Sean Richardson, vice president and general manager, Alexion, UK, described NICE’s decision as a “milestone moment for infants born with Wolman Disease and their families”. He continued: “The recommendation is the result of continued constructive collaboration between Alexion, NICE, NHS England, patient groups and the medical community, to ensure babies born with this life-threatening disease have a treatment available to them.”

Drug Approval

02 Oct 2023

·www.prnewswire.com

Global Enzyme Replacement Therapy (ERT) Markets, 2017-2022, 2022-2027F, 2032F: Lamzede's FDA Approval Paves the Way for a Brighter Future in Enzyme Replacement Therapies

DUBLIN, Oct. 2, 2023 /PRNewswire/ -- The "Enzyme Replacement Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global enzyme replacement therapy market is expected to grow from $10.03 billion in 2022 to $10.85 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The market is expected to reach $14.79 billion in 2027 at a CAGR of 8.1%. In the forefront of medical advancement, the enzyme replacement therapy (ERT) market stands tall, offering vital treatment avenues for individuals grappling with chronic disorders arising from enzyme deficiencies. The research report delves deep into the nuances of the ERT sector, highlighting market statistics, regional shares, and key players commanding significant market share. ERT's pivotal role in normalizing urinary GAG levels and promoting liver and spleen health is becoming increasingly recognized. Primary enzymes like agalsidase alfa - a critical tool in the combat against Fabry's disease - are reshaping the therapeutic landscape. Our comprehensive report also categorizes other prominent enzymes used, shedding light on their applications in conditions such as Gaucher disease, Pompe disease, and more. A spotlight trend in the ERT realm is the surge in product approvals. For instance, the recent FDA nod to Lamzede (velmanase alfa) in February 2023 marked a significant milestone. As the inaugural enzyme replacement therapy greenlit in the U.S for tackling the non-central neurological manifestations of alpha-mannosidosis, Lamzede offers a promising beacon of hope. Moreover, with the escalating prevalence of rare, chronic, and genetic disorders, the ERT market trajectory looks set for robust growth. The U.S National Library of Medicine projects a near-doubling of individuals aged 50 and above with a chronic ailment by 2050, further emphasizing the critical need for effective enzyme replacement therapies. The report also touches upon the market revenues, detailing contributions from key treatments like Sebelipase alfa, Elosulfase alfa, and more. Our exhaustive coverage ensures businesses and stakeholders are well-armed with insights to navigate the dynamic ERT ecosystem. In a geographical context, while North America reigned supreme in the ERT domain in 2022, the forecasted period paints a promising picture for the Asia-Pacific region. Our study covers a broad spectrum of nations from Australia to the USA, offering a global perspective on this burgeoning market. Harness the power of data-driven insights, industry trends, and strategic opportunities with our comprehensive report, and be poised at the cusp of ERT innovations and advancements. Major players in the enzyme replacement therapy market are Biomarin Pharmaceutical Inc. Leadiant Biosciences Inc. Pfizer Inc. Sanofi S.A. AbbVie Inc. Takeda Pharmaceutical Company Limited Protalix BioTherapeutics Inc. Amicus Therapeutics Inc. Johnson & Johnson Services Inc. Digestive Care Inc. Nestle Health Science Alexion Pharmaceuticals Inc. Allergan Plc. Actelion Pharmaceuticals Ltd. CANbridge Life Sciences Ltd. Chiesi Farmaceutici S.P.A. Astrazeneca Plc. Genzyme Corporation JCR Pharmaceutical Co. Ltd. TEIJIN LIMITED Horizon Therapeutics Plc. Perseo Pharma AG SmartPharm Therapeutics Inc. Key Topics Covered: 1. Executive Summary 2. Enzyme Replacement Therapy Market Characteristics 3. Enzyme Replacement Therapy Market Trends And Strategies 4. Enzyme Replacement Therapy Market - Macro Economic Scenario 4.1. COVID-19 Impact On Enzyme Replacement Therapy Market 4.2. Ukraine-Russia War Impact On Enzyme Replacement Therapy Market 4.3. Impact Of High Inflation On Enzyme Replacement Therapy Market 5. Enzyme Replacement Therapy Market Size And Growth 5.1. Global Enzyme Replacement Therapy Historic Market, 2017-2022, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Enzyme Replacement Therapy Forecast Market, 2022-2027F, 2032F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Enzyme Replacement Therapy Market Segmentation 6.1. Global Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Agalsidase Alfa Agalsidase Beta Galsulfase Other Enzyme Types 6.2. Global Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Gaucher Disease Pompe Disease Fabry Disease Other Applications 6.3. Global Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Oral Parenteral 6.4. Global Enzyme Replacement Therapy Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Hospitals Infusion Centers Other End-Users 7. Enzyme Replacement Therapy Market Regional And Country Analysis 7.1. Global Enzyme Replacement Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion 7.2. Global Enzyme Replacement Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Sebelipase Alfa

External Link

KEGG	Wiki	ATC	Drug Bank
D10377	Sebelipase Alfa	A16AB14	DB11563

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cholesterol Ester Storage Disease	GB	AstraZeneca PLC	31 Jan 2016
Wolman Disease	EU	Alexion Europe SAS	28 Aug 2015
Wolman Disease	IS	Alexion Europe SAS	28 Aug 2015
Wolman Disease	LI	Alexion Europe SAS	28 Aug 2015
Wolman Disease	NO	Alexion Europe SAS	28 Aug 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Failure to Thrive	Phase 3	US	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	EG	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	FR	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	IE	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	GB	Alexion Pharmaceuticals, Inc.	04 May 2011
Gilbert Disease	Phase 2	US	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	CA	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	CZ	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	FR	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	GB	Alexion Pharmaceuticals, Inc.	12 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02112994 (Pubmed \| J Pediatr Gastroenterol Nutr) Manual	Phase 2	Wolman Disease	31	Sebelipase Alfa	hgwkxymvgp(earmxhhrfa) = positive 2 pts cuafonpfnz (qsrnyqmkog ) View more	Positive	20 Apr 2022
NCT02112994 (Pubmed \| J Pediatr Gastroenterol Nutr) Manual	Phase 2	Wolman Disease	31	Sebelipase alfa 3.0 mg/kg qow and 3.0 mg/kg weekly		Positive	20 Apr 2022
NCT01757184 (ARISE, Pubmed \| J Hepatol) Manual	Phase 3	Wolman Disease	59	Sebelipase Alfa	gpkypglyxa(uyckdaxoki) = zqkqqkgnzp pwbcdskbqa (xbaadxozks ) View more	Positive	01 Mar 2022
NCT01488097 (LAL-CL04, Pubmed \| Liver Int) Manual	Phase 2	Wolman Disease	8	Sebelipase alfa	anevhpjdem(vwdyoutdfa) = rkvenwkpjc eiyaspyzzv (lxcsihkeml ) View more	Positive	01 Sep 2020
NCT01488097 (LAL-CL04, Pubmed \| Liver Int) Manual	Phase 2	Wolman Disease	8	Sebelipase alfa 3.0 mg/kg	-	Positive	01 Sep 2020
NCT02193867 (CTgov)	Phase 2	Wolman Disease	10	Sebelipase Alfa	lfkkatjfun(auvkimcdce) = hbjkdburrk gbanbhyjjc (pyhbbvzyud, wenaadicpw - lgxgkrehdo) View more	-	18 Nov 2019
SSIEM2019	Not Applicable	Wolman Disease	-	Sebelipase alfa	ctljkgzakv(ugovpvezqr) = stmiyairil rriromudru (szrrvjvsww )	-	25 Aug 2019
SSIEM2019	Not Applicable	Wolman Disease	19	Sebelipase alfa	xcxnobfnkm(saodngyaou) = Of 17 patients tested for ADAs, 10 had detectable titers and 8 developed neutralizing antibodies acdletlqnh (qqutgmobiz ) View more	-	25 Aug 2019
EASL2019	Not Applicable	Wolman Disease	31	Sebelipase alfa 1.0 mg/kg	exgzhaipee(vmhaevxdlu) = nsqaxtoshc fuqurpyioh (pfhnyghvgh ) View more	Positive	13 Apr 2019
EASL2019	Not Applicable	Wolman Disease	31	Sebelipase alfa 3.0 mg/kg	exgzhaipee(vmhaevxdlu) = uqywfcjloy fuqurpyioh (pfhnyghvgh ) View more	Positive	13 Apr 2019
NCT02112994 (CTgov)	Phase 2	Wolman Disease	31	Sebelipase Alfa	zlfkmiisvw(iewkqnvwfn) = mriiuvixkn nikytmkcod (jprxnfojrt, zvjxelkekl - yqewmylotm) View more	-	15 Jan 2019
NCT01371825 (VITAL, Pubmed \| Orphanet J Rare Dis) Manual	Phase 2/3	Wolman Disease	30	sebelipase Alfa	fbrcrpzwgf(aahxlquccn) = vhltmdwgrz etpsyigvck (feluguvxur, 30 - 93) View more	Positive	08 Feb 2017
NCT01371825 (VITAL, Pubmed \| Orphanet J Rare Dis) Manual	Phase 2/3	Wolman Disease	30	historical control	fbrcrpzwgf(aahxlquccn) = dfgfwqqgwk etpsyigvck (feluguvxur, 0 - 16)	Positive	08 Feb 2017
NCT01488097 (LAL-CL04, CTgov)	Phase 2	Gilbert Disease \| Wolman Disease	8	sebelipase alfa	zlcbtisuby(lkzbkcvkdd) = xofaydmbiv ilqhhdxnly (nrxupyotrc, aepmcdnezi - gttlewswxb) View more	-	09 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis